Libtayo® (cemiplimab) receives positive chmp opinion for the treatment in europe of two advanced cancers

Tarrytown, n.y. and paris, may 24, 2021 /prnewswire/ -- libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have ≥50% pd-l1 expression libtayo also recommended for approval in patients with advanced basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor chmp has now issued three positive opinions for libtayo in advanced cancers regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted positive opinions for libtayo® (cemiplimab) as monotherapy in two advanced cancers.
REGN Ratings Summary
REGN Quant Ranking